



06-27-01

#5

UP-1643

RECEIVED

Docket Number	CASE 4-20039C
JUL 02 2001	

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL138 342 594 US Express Mail Label Number	6/26/2001 Date of Deposit
---	------------------------------

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1643

NICO CERLETTI

Examiner: D. Romeo

APPLICATION NO: 09/813,271

FILED: MARCH 20, 2001

FOR: NEW PROCESS FOR THE PRODUCTION OF
BIOLOGICALLY ACTIVE PROTEIN

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JUN 29 2001
TECHNOLOGY CENTER 1700

LETTER TO REQUEST TO TRANSFER PREVIOUSLY FILED SEQUENCE
INFORMATION

Sir:

In response to the Office Communication dated April 26, 2001, the PTO is requested to transfer the computer readable copy from the parent application to the instant application, as permitted by MPEP 2422.05. The communication had a shortened statutory set to expire on June 26, 2001.

The paper copy of the Sequence Listing in the instant application, SN 09/303,970 is identical to the computer readable copy of the Sequence Listing filed in parent application SN 09/316,724, filed May 21, 1999. In accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the PTO will make the necessary

change in application number and filing date for the instant application. A copy of the notice to comply is enclosed.

Should the Office feel that telephonic communication with the applicants' representative would further the prosecution of the instant application, the Examiner is invited to telephone the undersigned.


No fees are believed due with this paper, but the Commissioner is hereby authorized to charge any fees which may be required, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation

Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940
20039 cont seq submission

Date: June 26, 2001

A handwritten signature in dark ink, appearing to read 'Hesna J. Pfeiffer', is written over a horizontal line.

Hesna J. Pfeiffer
Attorney for Applicant
Reg. No. 22,640



Page 1 of 2
RECEIVED

JUL 02 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/813,271	03/20/2001	Nico Cerletti	4-20039C/C1C1/USN

CONFIRMATION NO. 2623

001095
THOMAS HOXIE
NOVARTIS CORPORATION
PATENT AND TRADEMARK DEPT
564 MORRIS AVENUE
SUMMIT, NJ 079011027

FORMALITIES LETTER



Date Mailed: 04/26/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

A handwritten signature in black ink, appearing to be "J. O. O.", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE